Lexeo Therapeutics Inc. has provided an update on its gene therapy programs targeting cardiac diseases with significant unmet medical needs. The company highlighted LX2006, its clinical-stage program for Friedreich Ataxia $(FA)$ cardiomyopathy, the leading cause of death in individuals with FA. Interim clinical data indicate sustained or deepening improvements in both cardiac and neurological measures among most participants. The FDA has expressed openness to a Biologics License Application (BLA) submission for accelerated approval, incorporating data from ongoing and planned studies. Lexeo also reported progress on LX2020 for PKP2 arrhythmogenic cardiomyopathy, with safety and efficacy data expected in early January. The company emphasized the use of AAVrh10 vector technology, which has demonstrated increased cardiac targeting and favorable safety profiles in preclinical and clinical programs. You can access the full presentation through the link below.